NO20055536L - Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon - Google Patents

Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon

Info

Publication number: NO20055536L
Authority: NO; Norway
Prior art keywords: individuals; procedures; renal function; impaired renal; diuresis
Prior art date: 2003-04-25

Application number

NO20055536A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055536D0 (no

Inventor

Kenneth J Widder

Lauren Otsuki

Howard Dittrich

Scott Thomson

Roland Blantz

Original Assignee

Novacardia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-25

Filing date

2005-11-23

Publication date

2005-12-29

2005-11-23 Application filed by Novacardia Inc filed Critical Novacardia Inc

2005-11-23 Publication of NO20055536D0 publication Critical patent/NO20055536D0/no

2005-12-29 Publication of NO20055536L publication Critical patent/NO20055536L/no

Links

208000004880 Polyuria Diseases 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
206010062237 Renal impairment Diseases 0.000 title 1
230000035619 diuresis Effects 0.000 title 1
231100000857 poor renal function Toxicity 0.000 title 1
230000001882 diuretic effect Effects 0.000 abstract 3
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
150000001408 amides Chemical class 0.000 abstract 2
150000002148 esters Chemical class 0.000 abstract 2
230000001939 inductive effect Effects 0.000 abstract 2
239000002207 metabolite Substances 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
229960005305 adenosine Drugs 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000002083 iodinating effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
238000009966 trimming Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20055536A 2003-04-25 2005-11-23 Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon NO20055536L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46600703P	2003-04-25	2003-04-25
PCT/US2004/012518 WO2004096228A1 (en)	2003-04-25	2004-04-23	Method of improved diuresis in individuals with impaired renal function

Publications (2)

Publication Number	Publication Date
NO20055536D0 NO20055536D0 (no)	2005-11-23
NO20055536L true NO20055536L (no)	2005-12-29

Family

ID=33418325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055536A NO20055536L (no)	2003-04-25	2005-11-23	Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon

Country Status (16)

Country	Link
US (3)	US7579331B2 (pt)
EP (1)	EP1620107A1 (pt)
JP (1)	JP2006524699A (pt)
KR (1)	KR20060004959A (pt)
CN (1)	CN1859913A (pt)
AR (1)	AR044069A1 (pt)
AU (1)	AU2004233852A1 (pt)
BR (1)	BRPI0409699A (pt)
CA (1)	CA2522971A1 (pt)
MX (1)	MXPA05011371A (pt)
NO (1)	NO20055536L (pt)
NZ (1)	NZ543109A (pt)
RU (1)	RU2367442C2 (pt)
TW (1)	TW200500070A (pt)
WO (1)	WO2004096228A1 (pt)
ZA (1)	ZA200509311B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040229901A1 (en) *	2003-02-24	2004-11-18	Lauren Otsuki	Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011371A (es)	2003-04-25	2005-12-01	Novacardia Inc	Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
US20060293312A1 (en) *	2003-04-25	2006-12-28	Howard Dittrich	Method of improved diuresis in individuals with impaired renal function
CA2536975A1 (en) *	2003-08-28	2005-03-17	Nitromed, Inc.	Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
BRPI0509753A (pt) *	2004-04-16	2007-10-16	Novacardia Inc	composição farmacêutica e método de tratamento de doença cardiovascular
WO2006091716A2 (en) *	2005-02-24	2006-08-31	Nitromed, Inc.	Nitric oxide enhancing diuretic compounds, compositions and methods of use
EP1928414A2 (en) *	2005-04-22	2008-06-11	Novacardia, Inc.	Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
JPWO2007069675A1 (ja) *	2005-12-14	2009-05-28	協和発酵キリン株式会社	キサンチン誘導体の易吸収性経口製剤
AU2007235372A1 (en) *	2006-04-06	2007-10-18	Novacardia, Inc.	Co-administration of adenosine A1 receptor antagonists and anticonvulsants
EP2035092A2 (en) *	2006-06-16	2009-03-18	Novacardia, Inc.	Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
CN101466383A (zh) *	2006-06-16	2009-06-24	美国诺华卡迪亚公司	包含低频率投与aa1ra的肾功能延长改善
WO2008121882A1 (en) *	2007-03-29	2008-10-09	Novacardia, Inc.	Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) *	2007-03-29	2009-08-06	Howard Dittrich	Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE416810C (sv)	1977-10-14	1982-07-19	Draco Ab	Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
FR2531085A1 (fr)	1982-07-28	1984-02-03	Adir	Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4769377A (en)	1983-02-18	1988-09-06	The Johns Hopkins University	Adenosine receptor antagonists
DE8817122U1 (de)	1988-12-22	1993-02-04	Boehringer Ingelheim Kg, 55218 Ingelheim	Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5290782A (en)	1989-09-01	1994-03-01	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
SE9000207L (sv)	1990-01-22	1991-07-23	Nobel Chemicals Ab	Laekemedel samt anvaendningen av detsamma
DE4019892A1 (de)	1990-06-22	1992-01-02	Boehringer Ingelheim Kg	Neue xanthinderivate
AU2297192A (en)	1991-06-28	1993-01-25	Sepracor, Inc.	Optically pure s(-) nadolol for treatment of cardiovascular disorders
CA2093403C (en)	1992-04-08	1999-08-10	Fumio Suzuki	Therapeutic agent for parkinson's disease
TW252044B (pt)	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
DE4238367A1 (de)	1992-11-13	1994-05-19	Boehringer Ingelheim Kg	Diuretisches Mittel
US5395836A (en)	1993-04-07	1995-03-07	Kyowa Hakko Kogyo Co., Ltd.	8-tricycloalkyl xanthine derivatives
US5446046A (en)	1993-10-28	1995-08-29	University Of Florida Research Foundation	A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en)	1993-10-28	1998-04-07	University Of Florida Research Foundation, Inc.	N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
CN1049117C (zh)	1994-09-16	2000-02-09	赵明玉	预防和治疗偏头痛的偏头痛片
US6254889B1 (en)	1995-07-26	2001-07-03	Kyowa Hakko Kogyo Co., Ltd.	Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
ATE281835T1 (de)	1996-08-07	2004-11-15	Kyowa Hakko Kogyo Kk	Fettemulsion, die ein xanthinderivat enthält
DE19816857A1 (de)	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6187780B1 (en)	1998-04-16	2001-02-13	Boehringer Ingelheim Pharma Kg	Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
ATE252905T1 (de)	1998-04-24	2003-11-15	Biogen Inc	Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion
US20020115687A1 (en)	1998-04-24	2002-08-22	Evan Beckman	Method and composition for restoring diuretic and renal function
EP0970696A1 (en)	1998-05-05	2000-01-12	Kyowa Hakko Kogyo Co., Ltd.	Combination of loop diuretics with adenosine A1-receptor antagonists
UA74141C2 (uk)	1998-12-09	2005-11-15	Дж.Д. Сірл Енд Ко.	Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
CN100390178C (zh)	1999-11-12	2008-05-28	拜奥根Idec马萨诸塞公司	作为腺苷受体拮抗剂的多环烷基嘌呤
MXPA02004795A (es)	1999-11-12	2005-07-01	Biogen Inc	Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos.
US20050038017A1 (en)	1999-12-22	2005-02-17	Wolff Andrew A.	Method and composition for restoring diuretic and renal function
BR0115833A (pt)	2000-12-01	2003-10-28	Biogen Inc	Derivados condensados de purina como antagonistas de receptores de adenosina a1
HUP0302455A3 (en)	2000-12-18	2005-05-30	Novartis Ag	Combination pharmaceutical compositions containing amplodipine and benazepril and their use
UA80258C2 (en)	2001-09-06	2007-09-10	Biogen Inc	Methods of treating pulmonary disease
US20040229901A1 (en)	2003-02-24	2004-11-18	Lauren Otsuki	Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011371A (es)	2003-04-25	2005-12-01	Novacardia Inc	Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
US20060293312A1 (en)	2003-04-25	2006-12-28	Howard Dittrich	Method of improved diuresis in individuals with impaired renal function
US20050070524A1 (en)	2003-06-06	2005-03-31	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
BRPI0509753A (pt)	2004-04-16	2007-10-16	Novacardia Inc	composição farmacêutica e método de tratamento de doença cardiovascular
CA2565037A1 (en)	2004-04-28	2005-11-10	Cv Therapeutics, Inc.	Purine derivatives as a1 adenosine receptor antagonists
AU2007235372A1 (en)	2006-04-06	2007-10-18	Novacardia, Inc.	Co-administration of adenosine A1 receptor antagonists and anticonvulsants
CN101466383A (zh)	2006-06-16	2009-06-24	美国诺华卡迪亚公司	包含低频率投与aa1ra的肾功能延长改善
EP2035092A2 (en)	2006-06-16	2009-03-18	Novacardia, Inc.	Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
EP2061793A2 (en)	2006-08-22	2009-05-27	Novacardia, Inc.	Kw-3902 conjugates that do not cross the blood-brain barrier

2004
- 2004-04-23 MX MXPA05011371A patent/MXPA05011371A/es not_active Application Discontinuation
- 2004-04-23 CN CNA2004800105597A patent/CN1859913A/zh active Pending
- 2004-04-23 US US10/830,617 patent/US7579331B2/en not_active Expired - Fee Related
- 2004-04-23 JP JP2006513242A patent/JP2006524699A/ja not_active Withdrawn
- 2004-04-23 RU RU2005131938/15A patent/RU2367442C2/ru not_active IP Right Cessation
- 2004-04-23 AU AU2004233852A patent/AU2004233852A1/en not_active Abandoned
- 2004-04-23 BR BRPI0409699-1A patent/BRPI0409699A/pt not_active IP Right Cessation
- 2004-04-23 EP EP04760339A patent/EP1620107A1/en not_active Withdrawn
- 2004-04-23 TW TW093111522A patent/TW200500070A/zh unknown
- 2004-04-23 KR KR1020057020243A patent/KR20060004959A/ko not_active Ceased
- 2004-04-23 CA CA002522971A patent/CA2522971A1/en not_active Abandoned
- 2004-04-23 NZ NZ543109A patent/NZ543109A/en unknown
- 2004-04-23 WO PCT/US2004/012518 patent/WO2004096228A1/en not_active Ceased
- 2004-04-23 AR ARP040101381A patent/AR044069A1/es unknown
2005
- 2005-10-11 US US11/248,479 patent/US20060030572A1/en not_active Abandoned
- 2005-10-11 US US11/248,905 patent/US20060035911A1/en not_active Abandoned
- 2005-11-17 ZA ZA200509311A patent/ZA200509311B/en unknown
- 2005-11-23 NO NO20055536A patent/NO20055536L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20055536D0 (no)	2005-11-23
MXPA05011371A (es)	2005-12-01
RU2005131938A (ru)	2006-06-27
AR044069A1 (es)	2005-08-24
KR20060004959A (ko)	2006-01-16
EP1620107A1 (en)	2006-02-01
CA2522971A1 (en)	2004-11-11
NZ543109A (en)	2008-06-30
US20060035911A1 (en)	2006-02-16
US20060030572A1 (en)	2006-02-09
RU2367442C2 (ru)	2009-09-20
US20050004145A1 (en)	2005-01-06
ZA200509311B (en)	2006-10-25
BRPI0409699A (pt)	2006-04-18
CN1859913A (zh)	2006-11-08
WO2004096228A1 (en)	2004-11-11
US7579331B2 (en)	2009-08-25
JP2006524699A (ja)	2006-11-02
AU2004233852A1 (en)	2004-11-11
TW200500070A (en)	2005-01-01

Legal Events

Date	Code	Title	Description
2010-11-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20055536L (no)	2005-12-29	Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon
NO2025027I1 (no)	2025-06-13	Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
CL2007001918A1 (es)	2008-03-28	Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
WO2008061226A3 (en)	2008-07-31	Sustained-release formulations of topiramate
CY1118179T1 (el)	2017-06-28	Φαρμακευτικη συνθεση
EP1709585A4 (en)	2015-11-25	MULTI-DIMENSIONAL IMAGE RECONSTRUCTION
FR2864958B1 (fr)	2006-02-24	Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
CY1105120T1 (el)	2010-03-03	Η αντιμετωπιση αναπνευστικων νοσων
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2007149285A3 (en)	2008-04-24	Method of improved diuresis in individuals with impaired renal function
CU20100123A7 (es)	2011-10-14	Sales farmacéuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo y sus usos en terapia
BRPI0519124A2 (pt)	2008-12-23	composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
ECSP055701A (es)	2005-05-30	Nuevos derivados de pirimidinamida y el uso de los mismos
DK1598333T3 (da)	2007-02-12	Fremgangsmåde til fremstilling af (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutan og syreadditionssalte heraf samt anvendelse til syntese af ivabradin og syreadditionssalte heraf med farmaceutisk acceptable syrer
NO341573B1 (no)	2017-12-04	Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
WO2005027977A3 (en)	2005-12-08	Diclofenac compositions for the treatment of skin disorders
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
CY1106148T1 (el)	2011-06-08	Φαρμακευτικη συνθεση πepιλαμβανουσα ν-((1-κ-βουτυλ-4-πιπepιδινυλ) μεθυλ)-3,4-διϋδρο-2η-(1,3) οξαζινο (3,2-α) ινδολο-10-καρβοξαμιδιο ή αλας και μεθοδος για παρασκευη αυτης που πepιλαμβανει ξηρη κοκκοποιηση
SG152257A1 (en)	2009-05-29	Topical preparation containing ambroxol
FR2873690B1 (fr)	2006-10-13	Derives d'oxopiperidine, leur preparation et leur application en therapeutique
JP2004505922A5 (pt)	2005-03-03
FR2880023B1 (fr)	2007-02-23	Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
MXPA06003122A (es)	2006-05-31	Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
BRPI0607413A2 (pt)	2009-09-01	composição farmacêutica compreendendo derivados de indolilmaleimida
WO2005058341A3 (en)	2005-12-08	Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases